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effectiveness literature. METHODS: A literature search was con-
ducted in MEDLINE to identify the published articles on HF
from 1993 to 2007 with a focus on economic evaluations and
resource use. Six review articles were found which summarized
31 economic studies for ACE inhibitors, beta-blockers and
digoxin through 2004. None of the review articles had summa-
rized the studies for ARBs, aldosterone receptor blockers, or
evidence from real-world studies. RESULTS: After excluding
studies summarized in the previous review papers, we found 29
new economic analyses for drugs used to treat HF. Among these,
22 studies were based on data available from clinical trials. These
included 14 cost-effectiveness analyses (CEA), 1 CEA/cost-utility
analysis, 1 CEA/cost-consequence analysis, 4 CEA/cost-beneﬁt
analyses (CBA), 1 CBA and 1 budget impact analysis. The
remaining analyses were studies conducted using real-world
data. Five studies compared ARBs to placebos or ACE inhibitors,
out of which four suggested cost-savings or cost-effectiveness for
ARBs, and one showed higher costs for ARBs. For the remaining
drugs, evidence that treatment was cost-saving was observed in
16 studies and that the treatment had favorable cost-effectiveness
ratio was observed in 7 studies. Finally, one study comparing
costs among beta-blockers found bisoprolol to be the most cost-
effective drug. CONCLUSION: Economic studies analyzing
drugs used to treat HF can help in making rational decisions
regarding provision of care. However, there is need of more
comparative economic studies between same class drugs to
inform prescription drug decisions.
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OBJECTIVE: Evidence demonstrates a strong association
between reductions in LDL-C achieved with statin therapy and
reductions in cardiovascular events. Several cost-effectiveness
analyses have incorporated LDL-C reduction, which is a “surro-
gate endpoint”, as indicator for effectiveness of interventions in
their models. Interpretations of cost-effectiveness analyses with
surrogate endpoints may confuse decision-makers. Therefore,
clinically important endpoints (hard endpoints) such as cardio-
vascular events may be a better alternative to comprehend the
magnitude of the cost-effectiveness of therapeutics. The objective
is to estimate cost savings through cardiovascular event reduction
correlated with LDL-C reduction in patients with hypercholester-
olemia on statin therapy using pragmatic head-to-head RCTs
from a Canadian perspective. METHODS: Reducing LDL-C was
incorporated into an economic analysis through a reduction in
cardiovascular (cardiac and cerebrovascular) events. Data for
LDL-C reduction from a head-to-head RCT [Am Heart J
2002;144:1036–43]; rosuvastatin (starting 5 mg) versus simvas-
tatin (starting 20 mg) with up-titration doses; and distribution of
cardiovascular risk for users [N = 100,000, 5 years] in Canadian
population [Clin Invest Med 2007;30:E63–E69]. Medical costs
are from the perspective of the Canadian health care system.
RESULTS: It is estimated that approximate acquisition costs for
simvastatin is more than $14 million less than acquisition costs
for rosuvastatin. Health care cost-savings through cardiovas-
cular events prevention related to statin therapy are estimated
as follows: Non-fatal myocardial infarction, rosuvastatin
($97,488,572) and simvastatin ($88,086,070); ischemic stroke,
rosuvastatin ($63,178,674)and simvastatin ($57,085,510). Rosu-
vastatin saves almost $15.5 (95%CI: $14.8, $16.2) million com-
pared to simvastatin due to cardiovascular events reduction.
Rosuvastatin and simvastatin can prevent 3161 and 2857 deaths,
respectively. CONCLUSION: Although the acquisition cost for
simvastatin is much less than that for rosuvastatin, the economic
beneﬁts of dyslipidemia management with rosuvastatin in the
Canadian population is estimated to be signiﬁcantly superior to
simvastatin therapy through a reduction in costs associated with
the management of cardiovascular events and sequelae.
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OBJECTIVE: To assess the cost-effectiveness of LDL cholesterol
reduction based upon the 2004 NCEP guideline update for ator-
vastatin, lovastatin, rosuvastatin, simvastatin, atorvastatin plus
ezetimibe, lovastatin plus extended-release niacin, and simva-
statin plus ezetimibe from a third-party payer’s perspective.
METHODS: Literature-based decision analyses were conducted
to evaluate direct costs, treatment outcomes deﬁned as LDL goals
of <70 and <100 mg/dl, and clinically-signiﬁcant adverse events.
Each of the decision trees consisted of four initial monotherapy
treatment arms and also considered combination therapy versus
dose titration if treatment goals were not achieved. Base cases
were deﬁned according to NCEP high-risk patient classiﬁcations
and ﬁve categories of baseline LDL levels from the 1999–2002
National Health and Nutrition Examination Survey (NHANES).
Meta-analyses were performed to estimate percent LDL reduc-
tions for each agent and for each dose. Monte Carlo simulations
and probabilistic sensitivity analyses were used to yield incre-
mental cost-effectiveness ratios, conﬁdence intervals, and graphi-
cal representations of ﬁndings. One-way sensitivity analyses were
conducted on key variables of uncertainty and costs. RESULTS:
Overall, costs were observed to higher and effectiveness lower
among patients seeking a <70 mg/dl goal. Simvastatin was found
to be the most cost-effective treatment option for both
<70 mg/dL and <100 mg/dl goals and for each baseline LDL
cholesterol strata. Combination therapy was more cost-effective
compared to dose titration among the <70 mg/dl goal and in
those requiring LDL reductions above 45%. Analyses indicated
that the recent generic pricing of simvastatin substantially
impacted results. CONCLUSION: From a third-party payer per-
spective and among high-risk patients, simvastatin (including
monotherapy and combination with ezetimibe), was observed to
be the most cost-effective treatment option for LDL treatment
goals of <70 and <100 mg/dl. Further research is warranted
concerning combination therapies and in evaluating additional
surrogate outcomes such as high-density lipoprotein (HDL).
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OBJECTIVE: The REACH Registry shows that the rate of death,
myocardial infarctions (MI) and ischaemic strokes (IS) increase
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as the number of symptomatic arterial disease locations
increases. A cost-utility analysis was undertaken comparing two
years of clopidogrel treatment with aspirin treatment for patients
with a previous history of MI, who then sustain an IS or a
peripheral arterial disease (PAD) event. These patients are
referred to as ‘high-risk’. METHODS: A model was constructed
to simulate hypothetical ‘high-risk’ patients. The time horizon
was that of patient lifetime with only direct medical costs con-
sidered. Health states included were vascular death, non-fatal IS
events and non-fatal MI events. The risk of future events in the
‘high-risk’ group compared with patients who had sustained a
single event (MI, IS or PAD) was calculated from the CAPRIE
trial and showed an 81% increase. This ratio was applied to
previously published risks of vascular death, non-fatal IS and
non-fatal MI for UK patients with a single event to calculate the
event rates for ‘high-risk’ patients. The relative risks (and 95%
conﬁdence intervals) of clopidogrel compared with aspirin in
‘high-risk’ patients in the CAPRIE trial were 0.87 (0.63–1.19),
0.83 (0.60–1.15) and 0.53 (0.32–0.86) for vascular death, non-
fatal IS and non-fatal MI events respectively. Costs and utilities
associated with events were taken from literature reviews and
were discounted at 3.5% per annum. Probabilistic sensitivity
analyses were undertaken. RESULTS: The mean cost per QALY
for clopidogrel compared with aspirin was 5443 (95% conﬁ-
dence interval 2332 to dominated). The probability of the cost
per QALY being below 20,000, a signiﬁcant threshold for
cost-effectiveness in the UK, was 79%. CONCLUSION: The
model suggests that, in patients with a previous MI event and
a subsequent IS or PAD event, clopidogrel can be considered
cost-effective compared with aspirin in terms of current UK
thresholds.
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OBJECTIVE: Proper diagnosis of Deep Vein Thrombosis (DVT)
at the earliest time is very important so that appropriate therapy
can be initiated. Various diagnostic tests have been developed for
DVT, but most of them have poor sensitivity and speciﬁcity. Due
to the above issues, it is very important that diagnosis strategies
be developed which are cost-effective. METHODS: Cost-
effectiveness was analyzed using a decision model from TreeAge
Pro Suite 2007 software. Outcomes considered were costs,
adverse events and quality adjusted life years (QALYs). Prob-
abilities were calculated using Bayes’ revision method that uti-
lized sensitivity and speciﬁcity of the diagnostic tests along with
the pretest probability of developing the disease. Quality of life
and costs data were pooled from literature reviews. QALYs were
calculated using life expectancy tables. Costs in pounds were
converted to US dollars and adjusted through use of Consumer
Price Index data from Bureau of Labor Statistics. RESULTS:
With a cost-effectiveness ratio of $32.4995 per QALY, the fol-
lowing strategy dominated other alternate strategies—Perform
venography if D-dimer test is positive. Otherwise, if D-dimer test
is negative then no treatment is given. If venography shows
abnormal results, treatment is given otherwise for normal results,
no treatment is given. Sensitivity analysis showed that this strat-
egy remained cost-effective even when all costs were varied by
25%. The model results were affected by the sensitivity of the
diagnostic tests. CONCLUSION: Based on this analysis, it would
be cost-effective if symptomatic patients are diagnosed with the
strategy after classifying them according to Wells score. Further
research needs to be done to see if cost of venography is offset by
decrease in hospitalization of those who later develop severe
form of DVT. Health care providers should consider patient
population distribution among the risk groups deﬁned by Wells
score before generalizing the ﬁnding.
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OBJECTIVE: This study was aimed to evaluate the economic
beneﬁts of clinical pharmacy service in hyperlipidaemic manage-
ment in accordance to the ATP III guidelines. METHODS: A
clinical pharmacy service was developed at the lipid clinic of
Prince of Wales Hospital (PWH) between October 2005 and
October 2007. In the intervention group, patients attended edu-
cational visits conducted by a clinical pharmacist. Medication
compliance and the proper use of drugs were assessed. Monthly
telephone follow-ups were made to check on the progress of
patients. The time spent by the pharmacist was recorded. In the
control group, patients received usual medical care with no phar-
macist intervention. RESULTS: A total of 300 patients were
recruited (150 in the intervention group and 150 in the control
group). Intervention group achieved 23.6%, 15.3%, and 22.3%
mean reduction in LDL-C, total cholesterol and triglyceride
levels, respectively, compared with 3.7%, 5.2%, and 2.7% in the
control group. A sustained reduction in total cholesterol of 1%
is associated with a 2–3% reduction in CHD risk. Pharmacist
conducted mean of 3.34 + 0.7 educational visits and 16.3 + 3.3
telephone follow-up calls. The overall time spent was 3.08
minutes per patient per week. The average monthly salary of a
hospital pharmacist was HK$30,000 (HK$7.8 = USD$1). In
previously published data, 0.39 patients per year at the PWH
lipid clinic experienced acute myocardial infarction (AMI) and
required HK$28,800 medical cost annually. Clinical pharmacy
service reduced the CHD risk of these patients and prevented the
development of an AMI, providing a potential cost saving of
HK$28,600 (which was 99% cost reduction) per patient per
year at PWH. (Estimated cost of pharmacist to manage 0.39
patients per year is HK$182.18). CONCLUSION: Clinical phar-
macy service is potentially a cost-effective way to improve the
management of hyperlipidaemia alongside with routine physi-
cian care.
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OBJECTIVE: To assess long-term reduction of cardiovascular
(CV) events and cost-effectiveness of the use of rosuvastatin
(RSV), atorvastatin (ATV), simvastatin (SIM) and pravastatin
(PRA) in Mexican patients over 55 years old. METHODS: Efﬁ-
cacy data from STELLAR clinical trial (total cholesterol -TC-,
LDL-C; HDL-C, triglycerides -TG-) was used as input to the
model. Based on Framingham risk equations, 4 gender/risk
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